Session Information
Date: Wednesday, June 7, 2017
Session Title: Parkinson's Disease: Genetics
Session Time: 1:15pm-2:45pm
Location: Exhibit Hall C
Objective: To compare the latency between onset of Parkinson disease (PD) symptoms and onset of motor and non-motor complications of PD, between G2019S LRRK2 mutation carriers with PD and matched controls with PD.
Background: The autosomal dominant LRRK2 mutation is the most common genetic etiology for late onset PD. It is more prevalent in Ashkenazi Jewish (AJ) patients with PD compared to non-AJ patients with PD in the United States. Across several studies, the LRRK2 G2019S positive PD phenotype was similar when compared with LRRK2 negative PD.
Methods: 251 subjects began and 231 completed LRRK2 G2019S mutation testing and reported overall duration of PD symptoms as well as duration of several motor and non-motor PD complications. In this sub-analysis, we compared the interval from onset of PD to onset of motor and non-motor complications (INT), between 9 LRRK2 positive subjects and 19 LRRK2 negative controls matched for age, PD duration, education, and gender. We utilized log-rank tests to compare INT between LRRK2+ and LRRK2- groups.
Results: Of 231 subjects with PD (23.4% AJ), 9 were LRRK2 G2019S positive. We found no significant difference between LRRK2+ subjects and controls in INT to development of motor fluctuation (p= 0.897), dyskinesia (p= 0.478), memory loss (p=0.498), urinary control (p=0.402), dizziness (p=0.261), hallucinations (p=0.180), falls (p=0.407), or freezing of gait (p=0.612).
Conclusions: There was no significant difference in latency from onset of PD symptoms to development of motor and non-motor complications, between LRRK2 positive PD and matched controls. This confirms the similarity in phenotype reported in the literature between LRRK2 and sporadic PD. Larger clinical studies will be necessary in order to further elucidate the pathologic and clinical evolution of symptoms in LRRK2 positive PD.
To cite this abstract in AMA style:
S. Gunzler, D. Riley, A. Wilson-Delfosse, S. Chen, J. Mieyal, C. Tatsuoka. Interval from onset of Parkinson disease to onset of motor and non-motor complications in Leucine-rich repeat kinase 2 (LRRK2) G2019S positive versus matched PD controls [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/interval-from-onset-of-parkinson-disease-to-onset-of-motor-and-non-motor-complications-in-leucine-rich-repeat-kinase-2-lrrk2-g2019s-positive-versus-matched-pd-controls/. Accessed June 15, 2025.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/interval-from-onset-of-parkinson-disease-to-onset-of-motor-and-non-motor-complications-in-leucine-rich-repeat-kinase-2-lrrk2-g2019s-positive-versus-matched-pd-controls/